AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments.
Company Details
- Employees
- 36
- Address
- Ambachtenlaan 1, Heverlee,flemish Region 3001,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://astrivax.com/
- Keywords
- to drive our mission forward.
- HQ
- Heverlee, Flemish Region
Astrivax Therapeutics Questions
Astrivax Therapeutics's website is https://astrivax.com/
Astrivax Therapeutics's LinkedIn profile is https://be.linkedin.com/company/astrivax
Astrivax Therapeutics has
36 employees.
View email and phone details for 36
employees at Astrivax Therapeutics.
Astrivax Therapeutics's industry is
Biotechnology Research
Astrivax Therapeutics's top competitors are
Trellis,
Esobiotec,
Elkedonia,
Pantera,
Epics Therapeutics,
Onco3r Therapeutics,
Augustine Therapeutics,
Vicebio,
Theratrame,
Spica Therapeutics.
Astrivax Therapeutics's categories are Biotechnology Research
